xRead - September 2022

Wise et al.

Page 403

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.10.d. Evidence for the use of combination intranasal corticosteroids and intranasal antihistamine in the treatment of allergic rhinitis Study Year LOE Study design Study groups Clinical endpoint Conclusion Berger et al. 1486 2016 1b DBRCT 1 AzeFlu; 2 Placebo rTNSS, rTOSS, PRQLQ AzeFlu superior to placebo for symptoms and QOL improvement in children; symptoms improved when children self-rate. Meltzer et al. 1487 2013 1b DBRCT 1 AzeFlu; 2 Placebo rTNSS, rTOSS AzeFlu superior to placebo for all symptoms. Price et al. 1488 2013 1b DBRCT 1 AzeFlu; 2 Fluticasone propionate rTNSS, symptom free days AzeFlu superior to fluticasone for symptom reduction; faster onset. Carr et al. 1489 2012 1b DBRCT 1 AzeFlu; 2 Azelastine; 3 Fluticasone propionate; 4 Placebo rTNSS, rTOSS, RQLQ AzeFlu superior to either spray alone for symptom and QOL improvement; faster onset. Meltzer et al. 1490 2012 1b DBRCT 1 AzeFlu; 2 Azelastine; 3 Fluticasone propionate; 4 Placebo rTNSS, rTOSS, RQLQ AzeFlu superior to either spray alone for symptom and QOL improvement. Salapatek et al. 1491 2011 1b DBRCT 1 Solubilized azelastine + budesonide (CDX-313); 2 Azelastine + budesonide suspension; 3 Placebo TNSS Both treatments superior to placebo; CDX-313 superior to suspension-type spray for symptoms and speed of onset. Hampel et al. 1492 2010 1b DBRCT 1 AzeFlu; 2 Azelastine; 3 Fluticasone propionate; 4 Placebo TNSS AzeFlu superior to either spray alone; all treatments superior to placebo. LaForce et al. 1493 2010 1b DBRCT 1 AzeFlu; TNSS No difference between treatments.

2 Olopatadine + fluticasone propionate

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.